Tscan Therapeutics (TCRX) Held by Superinvestors
TSCAN THERAPEUTICS INC (TCRX) is currently held by 1 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $1.30M based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Renaissance Technologies LLC is currently the largest disclosed institutional shareholder of TCRX tracked by InsiderSet, reporting ownership valued at approximately $1.30M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $297,202.976, representing an estimated loss of -77.15% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed TCRX value among the investors covered in this analysis. Major shareholders include Renaissance Technologies LLC, and several other long-term asset managers with concentrated positions in TSCAN THERAPEUTICS INC (TCRX).
This page ranks the largest institutional TCRX shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Jim Simons | 0.00% | 1,326,799 | $1,300,396 | $297,203 | -$1,003,193 | -77.15% |
Frequently asked questions about TCRX
Who are the largest superinvestors holding TCRX?
The largest superinvestors holding TCRX in the latest SEC Form 13F filings include Renaissance Technologies LLC. InsiderSet ranks these superinvestors by their latest reported TCRX position.
What does the TCRX superinvestors page include?
This page tracks TCRX positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. TSCAN THERAPEUTICS INC (TCRX) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold TCRX?
InsiderSet currently tracks 1 superinvestors reporting TCRX holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own TCRX.
How much TCRX stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $1.30M in TCRX holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were TCRX superinvestor holdings last updated?
The latest TCRX superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor TCRX holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its TCRX position after the reporting date.
Are superinvestors buying or selling TCRX?
Buying and selling can be analyzed by comparing TCRX positions across consecutive 13F reporting periods. InsiderSet's TCRX Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View TCRX ownership changes.
How have superinvestor TCRX holdings changed over time?
InsiderSet tracks TCRX holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.